Clinical Trials Directory

Trials / Completed

CompletedNCT00960245

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Sandoz · Industry
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.

Conditions

Interventions

TypeNameDescription
DRUGNadolol (1 x 80 mg) Tablets (Invamed, Inc)
DRUGCorgard (1 x 80 mg) Tablets (Bristol Laboratories)

Timeline

Start date
1994-07-01
Primary completion
1994-07-01
Completion
1994-07-01
First posted
2009-08-17
Last updated
2017-03-28

Source: ClinicalTrials.gov record NCT00960245. Inclusion in this directory is not an endorsement.